Skip to main content

Inhibikase Therapeutics, Inc 10-K for FY2023

Inhibikase Therapeutics, Inc. (IKT)

10-K 2024-03-27 For: 2023-12-31
View Original
Added on April 07, 2026

About this 10-K

Inhibikase Therapeutics, Inc filed this 10-K on March 27, 2024, covering the fiscal year ended December 31, 2023 (FY2023).

Headline figures

Fiscal year ended December 31, 2023, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$260.5K
up 111.0% from $123.44K a year earlier
Net loss
$19.03M
compared with a net loss of $18.05M a year earlier
Diluted EPS
-$3.57
compared with -$4.28 a year earlier